$TIL News
Last published 12h ago
- 12h agoTILInstil Bio, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 12h agoTILInstil Bio Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswire
- 3mo agoTILInstil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireDALLAS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its second quarter 2026
- 6mo agoTILInstil Bio Reports First Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireDALLAS, May 15, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its first quarter 2026 financial
- 7mo agoTILInstil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateGlobeNewswireCompany evaluating potential acquisitions and in-licensing opportunities to drive next phase of strategic development Cash position of $76.3 million as of December 31, 2025 expected to fund current operating plan beyond
- 1y agoTILInstil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswireDALLAS, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its third quarter 2025
- 1y agoTILInstil Bio Announces ImmuneOnco's Presentation of '2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)GlobeNewswireORR of 35% in previously treated squamous NSCLC patients with responses across PD-L1 TPS scores Differentiated structure of ‘2510 potentially results in best-in-class monotherapy activity in 2L+ NSCLC for PD-(L)1xVEGF
- 1y agoTILInstil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswireWith the clearance of the U.S. IND, initiation of the U.S. clinical trial of AXN-2510/IMM2510 ("‘2510") anticipated before the end of 2025 Updated ‘2510 monotherapy data in squamous-NSCLC to be presented at IASLC's 2025
- 1y agoTILImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in ChinaGlobeNewswirePartial responses observed in 80% of squamous NSCLC front-line patients and in 46% of non-squamous NSCLC front-line patients Safety profile supports further clinical development, with no dose-limiting toxicities
- 1y agoTILInstil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid TumorsGlobeNewswireUS phase 1 trial of ‘2510 is expected to be initiated before the end of 2025 Anticipate ImmuneOnco sharing initial safety and efficacy results from phase 2 trial of ‘2510 + chemo in 1L NSCLC in the second half of 2025
- 1y agoALNYTILInstil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody ProgramGlobeNewswireDALLAS, June 11, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today announced the addition of John
- 1y agoTILInstil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical OfficerGlobeNewswireDALLAS, June 02, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel cancer therapies, today announced the appointment
- 1y agoTILInstil Bio to Participate in the 2025 Jefferies Global Healthcare ConferenceGlobeNewswireDALLAS, May 30, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (NASDAQ:TIL, ", Instil", )), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today announced that Bronson
- 1y agoTILInstil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in ChicagoGlobeNewswireDALLAS and SHANGHAI, May 23, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (NASDAQ:TIL, ", Instil", )) and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, "ImmuneOnco"), today announced that they
- 1y agoTILInstil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 ('2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated in 2H 2025GlobeNewswirePhase 3 trial of ‘2510 in combination with chemotherapy in first-line NSCLC anticipated to start in mid-2026 in China, subject to regulatory discussions Monotherapy US dose optimization Phase 1b/2 trial of ‘2510 in
- 1y agoTILInstil Bio Reports First Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswireEnrollment of 1L NSCLC patients in China trial of AXN-2510/IMM2510 in combination with chemotherapy is ongoing with initial clinical data by ImmuneOnco expected in 2H 2025 Initiation of U.S. clinical study
- 1y agoTILInstil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateGlobeNewswireClinical data for AXN-2510/IMM2510 monotherapy in relapsed/refractory NSCLC in China by ImmuneOnco, as well as additional safety data in other solid tumors, anticipated in 1H 2025 Enrollment of
- 1y agoTILInstil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific AntibodyGlobeNewswireImmuneOnco announced dosing of first patient in its recently initiated Phase 1b/2 clinical trial of IMM2510/SYN-2510 in combination with chemotherapy in patients with advanced NSCLC in China ImmuneOnco announced
- 2y agoTILInstil Bio Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswireLicensed SYN-2510, a potential best-in-class PD-L1xVEGF bispecific antibody, for global ex-China development and commercialization Clinical data update for SYN-2510/IMM2510 in China from ImmuneOnco anticipated in 1H
- 2y agoTILInstil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast CancerGlobeNewswireGlobal registrational strategy in first-line non-squamous and squamous non-small cell lung cancer (NSCLC)Global registrational strategy in first-line triple-negative breast cancer (TNBC)Initiation of Phase 1b/2
- 2y agoTILInstil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswireIn-licensed SYN-2510/IMM2510, a potentially best-in-class PD-L1xVEGF bispecific antibody, and SYN-27M/IMM27M, a next-generation ADCC-enhanced anti-CTLA-4 antibodyEntered into a 15-year lease for our cell therapy
- 2y agoTILInstil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 AntibodyGlobeNewswireDALLAS and SHANGHAI, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (NASDAQ:TIL, "Instil")) and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, "ImmuneOnco"), today announced a definitive
- 2y agoTILInstil Bio Reports First Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswireDALLAS, May 10, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its first quarter 2024
- 2y agoTILInstil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateGlobeNewswireDALLAS, March 21, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its fourth quarter and
- 2y agoTILInstil Bio Announces Strategic UpdateGlobeNewswireDALLAS, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil" or the "Company") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for
- 2y agoTILInstil Bio Announces Effective Date of 1-for-20 Reverse Stock SplitGlobeNewswireDALLAS, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil" or the "Company") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for
- 3y agoTILInstil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewswireDALLAS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of
- 3y agoTILInstil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual MeetingGlobeNewswireDALLAS, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of
- 3y agoTILInstil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewswireITIL-306, first CoStAR-TIL in clinical development, anticipated to start clinical trial ITIL-306-202 in 2H 2023 Initial data from ITIL-306-202 clinical trial anticipated in 2024 ITIL-306 operational in Manchester, UK
- 3y agoTILInstil Bio Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual ConferenceGlobeNewswirePresented data showing that folate receptor α (FRα)-CoStAR enhanced activity of TILs against autologous NSCLC, ovarian, and renal tumors ITIL-306, first CoStAR-TIL in clinical development, anticipated to resume clinical
- 3y agoTILInstil Bio Reports First Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewswireITIL-306 phase 1 study anticipated to receive CTA clearance from UK MHRA in 2H'2023 Anticipate initial clinical data from ITIL-306 phase 1 program in 2024 Cash runway beyond 2026 DALLAS, May 11, 2023 (GLOBE
- 3y agoTILInstil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdateGlobeNewswireInstil confirms cash runway beyond 2026 ITIL-306 phase 1 study anticipated to receive CTA clearance from UK MHRA in 2H'2023 Anticipate initial clinical data from ITIL-306 phase 1 program in 2024 DALLAS, March 31,
- 3y agoTILInstil Bio Announces Extension of Cash Runway Beyond 2026 with the Consolidation of R&D Operations to its Manchester, U.K. SiteGlobeNewswireCompany anticipates cash resources to provide runway beyond 2026 Initial clinical data from the ITIL-306 program expected in 2023 Instil is consolidating manufacturing and Phase 1 clinical trial of CoStAR-TIL™
- 3y agoTILInstil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal CancerGlobeNewswirePhase 1 trial of ITIL-306 in NSCLC, ovarian, and RCC re-opened to enrollment after voluntary pause Initial data readout for ITIL-306 expected in 2023 With recent reprioritization of clinical programs and corporate
- 3y agoTILNewman Ferrara LLP Announces Corporate Governance Investigations of Instil Bio, Inc. (TIL)Business WireNewman Ferrara LLP announced today that the firm is conducting investigations on behalf of shareholders of Instil Bio, Inc. (NASDAQ:TIL) ("Instil" or the "Company"). The investigations concern whether certain of the
- 3y agoTILInstil Bio Announces Prioritization of Genetically Engineered CoStAR-TIL Program with ITIL-306 in Advanced Solid Tumors and Reduction in WorkforceGlobeNewswireDiscontinuing unmodified TIL programs, including DELTA-1 and DELTA-2 trials of ITIL-168Prioritizing CoStAR-TIL programs for clinical development, including ITIL-306 in Phase 1 trial for NSCLC, ovarian, and renal cell
- 4y agoTILInstil Bio Announces Poster Presentations of CoStAR Platform at the 2022 Society for Immunotherapy of Cancer (SITC) Annual MeetingGlobeNewswireDALLAS, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of
- 4y agoTILInstil Bio Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the FirmGlobeNewswireBOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Instil Bio, Inc. (NASDAQ:TIL) for potential securities law violations. Investors who have lost money in their Instil Bio, Inc. investment
- 4y agoTILInstil Bio Announces Voluntary Pause of Enrollment in Ongoing Clinical Trials Related to ManufacturingGlobeNewswireVoluntarily paused enrollment in ITIL-168 and ITIL-306 trials pending outcome of manufacturing analysis and implementation of corrective actionsNo regulatory agency, including the FDA, has notified the Company of a
- 4y agoTILInstil Bio Announces First Patient Dosed with ITIL-306, our First Engineered TIL Therapy Using the CoStAR Platform Targeting Folate Receptor Alpha (FRα), in Non-Small Cell Lung CancerGlobeNewswire• ITIL-306 is a novel TIL therapy engineered with our CoStAR platform (CoStAR-TIL) targeting folate receptor alpha which is designed to boost TIL activity in the tumor microenvironment • CoStAR-T cells demonstrate
- 4y agoTILInstil Bio to Present at Jefferies Cell and Genetic Medicine SummitGlobeNewswireDALLAS, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today anno
- 4y agoTILInstil Bio to Present at Morgan Stanley Global Healthcare ConferenceGlobeNewswireDALLAS, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today anno
- 4y agoTILInstil Bio Announces Appointment of Tim Moore as Chief Operating OfficerGlobeNewswireDALLAS, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today anno
- 4y agoTILInstil Bio Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewswireCash runway expected to extend from 2024 into 2025 upon completion of anticipated sale-leaseback of Tarzana, CA manufacturing site DELTA-1 trial of ITIL-168 in advanced melanoma with registrational intent anticipated to complete enrollment in 1H 2023
- 4y agoTILInstil Bio Announces IND Clearance of First CoStAR-TIL program, ITIL-306, Designed to Enhance Activity in the Tumor MicroenvironmentGlobeNewswireFDA granted IND clearance for ITIL-306, Instil's first genetically-engineered CoStAR-TIL therapy for the treatment of NSCLC, RCC, and ovarian cancer Instil to present in vivo data with CoStAR T cells demonstrating enhanced expansion, persistence, and t
- 4y agoTILInstil Bio to Present Novel TIL Analytics at American Society of Gene and Cell Therapy (ASGCT)GlobeNewswireDALLAS, May 18, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announ
- 4y agoTILInstil Bio Reports First Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewswireTargeting completion of enrollment in registrational cohort of DELTA-1 in 2022 Presenting preclinical efficacy and safety data of CoStAR platform at ASCO 2022 Cash runway into 2024 through key clinical data expected in 2023 DALLAS, May 16, 2022
- 4y agoTILInstil Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate UpdateGlobeNewswire- Initiated DELTA-1, a Phase 2 trial of ITIL-168 in advanced melanoma with registrational intent - Received orphan drug and fast-track designation from the U.S. FDA for lead pipeline candidate, ITIL-168, in melanoma - Expansion of manufacturing cap
- 4y agoTILInstil Bio to Present at the Cowen 42nd Annual Health Care ConferenceGlobeNewswireDALLAS, March 02, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today anno
- 5y agoTILInstil Bio Announces Poster Presentations at the 2021 Society for Immunotherapy of Cancer (SITC) Annual MeetingGlobeNewswireDALLAS, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today annou